Original Paper

Protective Effect of Genistein on Cyclin D1 Expression in Malignant Ocular Melanoma Cells

Yasmin Sani Aprilliantina, Hera Dwi Novita, Elfina G Sadono, Rosy Aldina

ABSTRACT

Background: Ocular melanoma is a disorder that is rarely found but is deadly. Four tissues in the eye that can be attacked by melanoma include the uveal tract, conjunctiva, eyelids, and orbit. Uveal melanoma is the most common case, while melanoma conjunctiva is very rare. Objective: This study aimed to investigate the effect of giving genistein on cyclin D1 expression in malignant melanoma. Methods: When confluent, CRL1872 malignant melanoma cells will be divided into treatment groups, the group giving genistein dose 25 µM, the group giving genistein a dose of 50 µM, and the group giving genistein a dose of 100 µM. Cyclin D1 analysis was measured by immunofluorescence using confocal laser scan microscopy. Results: There was a significant increase in the expression of cyclin D1, in the group given genistein 25 µM and 50 µM (p < 0.05). For the administration of genistein dose of 100 µM, cyclin D1 expression decreased significantly compared to the control group (p < 0.05). Conclusion: It was concluded that genistein had a biphasic effect on cyclin D1 expression in malignant melanoma cells. Thus, genistein at the right dose can be a treatment of malignant melanoma.

Keywords: ocular melanoma, soybeans, chemotherapy, biphasic effect.

1. BACKGROUND

Ocular melanoma is a disorder that is rarely found but is deadly. Four tissues in the eye that can be attacked by melanoma include the uveal tract, conjunctiva, eyelids, and orbit. Uveal melanoma is the most common case, while melanoma conjunctiva is very rare. Melanoma is a primary ocular tumor in adults. The white skin incidence is 6.3 per million, in Hispanic 0.9, and 0.24 per million in blacks. Increased cases of melanoma conjunctiva are coming from environmental exposure, including exposure to ultraviolet light (1-3). Although diagnostic modalities and their treatment have developed, they involve conservative methods and maintain the eyeball, even to the assessment of oncogene status, but survival rates are still low (4-6).

Cyclin D1 is a nuclear protein encoded by the CCND1 gene. Cyclin D1 functions for growth promoters and tumor cell survival factors (7, 8). In skin melanoma, there is an amplification or overexpression of cyclin D1. This amplification is related to progression and high proliferation of these tumors (9-12). This excess expression is caused by a degradation defect that increases its stability (13, 14). The growth of melanoma can be activated by a decrease in p-16 and/or p-21 proteins so that it fails in cyclin D1 blockade (15). To the knowledge of the researchers, until now there have not been many studies evaluating the increase in Cyclin D1 expression in ocular melanoma. Previous studies have shown an increase in cyclin D1 expression associated with methylation and inactivation of the INK4 gene (gene for encoding p-16 tumor suppressor proteins) in uveal melanoma (16, 17).

Many studies state that consumption of soybeans can inhibit the growth of several types of cancer, including breast, prostate, and colon cancer. This claim is referred to genistein content in the range of 1.9-2.99 mg/gram soybeans. In healthy cells, genistein is not toxic (18-20). In some cancer cell lines, genistein can down-regulate cyclin D1. Down-regulation is associated with the arrest of G2/M (21-23). In melanoma cells, genistein induces cell arrest G0/G1 (24). Until now, as far as we know, not many studies have applied genistein to the expression of cyclin D1 in malignant melanoma cells. There-
Protective Effect of Genistein on Cyclin D1 Expression in Malignant Ocular Melanoma Cells

1. INTRODUCTION

Genistein, a natural flavonoid found in soy, has been shown to possess anti-cancer properties. It has been suggested to inhibit the expression of cyclin D1, a protein involved in the progression of cell cycle, in malignant melanoma cells. This study aims to investigate the protective effect of genistein on cyclin D1 expression in malignant melanoma cells.

2. OBJECTIVE

This study aimed to investigate the effect of giving genistein on cyclin D1 expression in malignant melanoma.

3. METHODS

3.1. In silico analysis

The chemical structure of genistein and daidzein was obtained from the PubChem database. The three-dimensional structure of cyclin D1 was obtained from the Protein Data Bank. The energy forming this compound was minimized, then the conversion of the format of GDP into SDF is done with OpenBabel 2.4.1 software. Molecular docking was done with Hex software. Ligand-protein interactions were analyzed by Discovery Client Studio 2019 software.

3.2. Cell line

Human melanoma cells CRL1872 were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in DMEM/Ham's F-12 medium containing 10% serum fetal bovine (FBS), supplemented with 5 µg/ml amphotericin, 100 µg/ml streptomycin, and 100 U/ml penicillin. Cells were grown in 24 cm² flasks at 37°C and 5% CO2 (25).

Cells that had reached confluence will be divided into four study groups (n = 6 per group), including the control group (without any treatment), the group given genistein dose of 25 µM, the group given genistein dose of 50 µM, and the group given genistein dose of 100 µM.

3.3. Genistein

Genistein 10 mg (MP Biomedicals) was dissolved in sterile aquadest so that a stock solution of 1 mg/ml was obtained. The stock solution was stored at 0°C. The stock solution will be diluted again using sterile aquadest to the desired dosage, covering 25 µM, 50 µM, and 100 µM.

3.4. Cyclin D1 analysis

Cyclin D1 analysis was carried out by immunofluorescent technique. The primary antibody used is anti-cyclin D1. The secondary antibody used is FITC. Cyclin D1 expression was assessed based on luminous density. Protein visualization was examined using confocal laser scanning microscopy Olympus fluo FV 10-ASW type 1.7. The units were expressed as intensity/mm².

3.5. Statistical analysis

Data was presented in mean ± standard deviation. Data were analyzed by ANOVA test using SPSS version 16 for Windows. In addition, a correlation test with the Pearson test was also carried out.

3.6. Ethics

This study was approved by local Ethics committee Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia.

4. RESULTS

In Figure 1 shows that genistein form bonds with the A cyclin D1 domain on several active sites, including ARG87, LEU91, LYS149, THR37, CYS38, ALA39, PRO40, SER41, ASN151, LYS147, and LEU148. This bond is composed of conventional hydrogen bonds. Also, Pi-sigma (LEU91), Pi-carbon (LYS149), and Van der Walls (THR37, CYS38, ALA39, PRO40, SER41, ASN151, LYS147, and LEU148) were also formed. The docking bond energy between genistein and cyclin D1 is ~ 241.2 kJ/mol.

The bond between Daidzein and Cyclin D1 can be seen in Figure 2. Interactions between Daidzein and Cyclin D1 have several active sites, including ARG179, ARG208, LEU215, TRP217, CYS218, ALA219, PRO220, SER221, ASN222, LYS224, LEU225, and LEU226.
ALA187, ALA65, PHE78, PRO79, GLU75, GLN176, GLN176, LYS180, GLN183, and THR184. For ARG179 an Amide Pi bond is formed. The pi-alkyl bond is formed in ALA187. Meanwhile, the van der Walls bond was also formed in ALA65, PHE78, PRO79, GLU75, GLN176, LYS180, GLN183, and THR184. This interaction has a docking bond energy of ~235.9 kJ/mol.

Figure 3 shows the expression of cyclin D1 in the control and treatment group. The expression of cyclin D1 was significantly higher in groups treated with genistein doses of 25 and 50 µM compared to the control (p < 0.05). There was a significant decrease in the cyclin D1 expression in the melanoma cells supplemented with a genistein dose of 100 µM compared to the control or genistein group doses of 25 and 50 µM (p < 0.05).

5. DISCUSSION
Cyclin D1 controls the cell cycle transition from the G1 phase to the S phase. Cyclin D1 overexpression is associated with cancer, resistance to chemotherapy, and is the target of cancer therapy (26).

In this study, we demonstrate the expression of cyclin D1 in malignant melanoma cells. The previous study proved the expression of cyclin D1 in melanocytes and melanoma cells 451 Lu cells and 1205 Lu cells (8).

In this study, the results of the in silico analysis showed that the interaction energy between genistein and cyclin D1 was more negative than the interaction between daidzein and cyclin D1. This interaction indicates that genistein is more accessible to interact with cyclin D1 than daidzein. Besides, the bonds formed in the genistein interaction are strong bonds. Furthermore, genistein was selected in an in vitro study. This study extends previous in silico findings of the communication of genistein and daidzein against cyclin D1 (27, 28).

The application of genistein to malignant melanoma was carried out by previous researchers. A previous study has shown that genistein can inhibit the growth of highly metastatic melanoma cells, namely K1735M2 cells and WM451 cells (29). Other studies prove that genistein can upregulate p-21 as a tumor suppressor protein (30). In this study, administration of genistein doses of 25 and 50 µM significantly increased the expression of cyclin D1 compared to controls. Meanwhile, for dose 100 µM significantly lowered the expression of cyclin D1 compared to the control. This result shows that genistein has a biphasic effect on the cyclin D1 in malignant melanoma. This finding is the novelty of this study. Previous studies have shown an increase in the expression of cyclin D1 in MCF-7 cells exposed to genistein dose of 10-5 M for 2 hours (31). In pancreatic cancer cells, genistein can downregulate cyclin D1 in doses of 10-40 µM (32). Genistein doses of 15 M and 20 M also downregulated cyclin D1 in hepatocellular carcinoma (HepG2 and Hep3B cells) (33). For the biphasic genistein effect, genistein at lower than physiological levels triggering a mitogenic impact, while superior pharmacological levels induce apoptosis (34-36). Other studies prove that genistein triggers the proliferation of MC3T3-E1 cells in doses of 10-7 to 10-10 M, while at high doses (10-4 M) it will inhibit proliferation (37).

6. CONCLUSION
We conclude that genistein had a biphasic effect on cyclin D1 expression in malignant melanoma cells. Thus, genistein at the right dose can be a treatment of malignant melanoma.

• Authors contribution: All author were involved in all steps of preparation of this article. Final proofreading was made by the first author.
• Conflict of interest: None declared.
• Financial support and sponsorship: Nil.

REFERENCES
1. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2009; 27: 122-133.
2. Blanco PL, Lim LA, Miyamoto C, Burnier MN. Uveal melanoma dormancy: an acceptable clinical endpoint? Melanoma Res. 2012; 22(5): 334-340.
3. Ozaki S, Vuyyuru R, Kageyama K, et al. Establishment and characterization of orthotopic mouse models for human uveal melanoma hepatic colonization. Am J Pathol. 2016; 186(1): 43-56.
4. Hawryluk EB, Fisher DE. Melanoma epidemiology, risk factors, and clinical phenotypes. In: Advances in malignant melanoma - clinical and research perspectives. Croatia: In-Tech. 2011: 4-28.
5. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005; 65(15): 6934-6942.
Protective Effect of Genistein on Cyclin D1 Expression in Malignant Ocular Melanoma Cells

6. Griewank KG, Schilling B, Scholz SL, et al. Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. Eur J Cancer. 2016; 57: 112-117. doi: 10.1016/j.ejca.2016.01.010. Epub 2016 Feb 23.

7. Yamamura M, Takata M, Miyasaki A, Saida T. Specific dermatoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ. Arch Dermatol. 2005; 141(11): 1413-1418.

8. Sauter RE, Yeo U, von Steppm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma Cancer Res. 2002; 62(2): 3200-3206.

9. Curtin JA, Fridyland J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20): 2135-2147.

10. Lebe B, Pabuccuoglu U, Ozor E. The significance of ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007; 15(2): 160-164.

11. Stefanaki C, Stefanaki K, Antoniou C, et al. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas. J Cutan Pathol. 2008; 35(9): 799-800.

12. Oba J, Nakahara T, Abe T, et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011; 62(2): 116-123. doi: 10.1016/j.jdermsci.2011.02.011.

13. Maeda I, Ohta T, Koizumi H, Fukuda M. In vitro ubiquitination of cyclin D1 by ROC1-CUL-1 and ROC1-CUL-3. FEBS Lett. 3; 494(3): 181-185.

14. Russell A, Thompson MA, Hendley J, et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene. 1999; 18(11): 1983-1991.

15. Ji Z, Flaherty KT, Taso H. Molecular therapeutic approaches to melanoma. Mol Aspect Med. 2010; 31(2): 194-204. doi: 10.1016/j.mam.2010.02.004.

16. van der Velden PA, Metzelaar-Blok JA, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16 (INK4a) expression in uveal melanoma. Cancer Res. 2001; 61(13): 5303-5306.

17. Coupland SE, Bechraakis N, Schuler A, et al. Expression pattern of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol. 1998; 82(8): 961-970.

18. Russo M, Russo GL, Daglia M. et al. Understanding genistein in cancer: the “good” and the “bad” effects: A review. Food Chem. 2016; 196: 589-600. doi: 10.1016/j.foodchem.2015.09.085.

19. Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, Nabavi SM. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015; 6(4): 408-419.

20. Yanhong H, Peng Y, Qinghong Z, Xiaoan Y. Genistein sensitizes ovarian carcinoma cells to chemotherapy by switching the cell cycle progression in vitro. J Med Colleges of PLA. 2009; 24(3): 125-135.

21. Wang LM, Ren DM. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem. 2010; 10(11): 1058-1070.

22. Kafer CM, Milner JA. The role of herbs and spices in cancer prevention. J Nutr Biochem. 2008; 19(6): 347-361.

23. Aggarwal BB, Shishodia S. Suppression of the nuclear factor B activation pathway by spice derived phytochemicals: reasoning for seasoning. Ann N Y Acad Sci. 2016; 1034: 434-441.

24. Kuzumaki T, Kobayashi T, Ishikawa K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem Biophys Res Commun. 1998; 251(1): 291-295.

25. Werengowska-Cieciewer K, Wcisniewski M, Terzyk AP, et al. Nanotube-mediated efficiency of cisplatin anticancer therapy. Carbon. 2014; 70: 46-58.

26. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009; 220: 292-296.

27. Dhananjaya K, Sibi G, Mallesha H, Ravikumar KR, Awasthi S. Insilico studies of daidzein and genistein with human estrogen receptor α. Asian Pacific J Trop Biomed. 2012; 2(3): s1747-s1753.

28. Yuseran H, Hartoyo E, Nurseta T, Kalim H. Molecular docking of genistein on estrogen receptors, promoter region of BCLX, caspase-3, Ki-67, cyclin D1, and telomere activity. J Taibah Univ Med Sci. 2019; 14(1): 79-87.

29. Wang HZ, Zhang Y, Xie LP, Yu XY, Zhang RQ. Effects of genistein and daidzein on the cell growth, cell cycle, and differentiation of human and murine melanoma cells. J Nutr Biochem. 2002; 13(7): 421-426.

30. Casagrande F, Darbon JM. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res. 2000; 258(1): 101-108.

31. Sakamoto T, Horiguchi H, Oguma E, Kayama F. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem. 2010; 21(9): 856-864.

32. Yi-jiang B, Min M, Wei S, Yan L. Genistein induced anticancer effects on pancreatic cancer cell lines involves mitochondrial apoptosis, G0/G1 cell cycle arrest and regulation of STAT3 signalling pathway. Phytomedicine. 2018; 38: 10-16. doi: 10.1016/j.phymed.2017.12.001.

33. Ma Y, Wang J, Liu L, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: Role of Akt and nuclear factor-kb. Cancer Lett. 2011; 301(1): 75-84.

34. Lavigne JA, Takahashi Y, Chandramouli GVR, et al. Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study. Breast Cancer Res Treat. 2008; 110(1): 85-98.

35. Seo HS, DeNardo DG, Jacquot Y, et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res & Treat. 2006; 99(2): 121-134.

36. Lee YS, Chen X, Anderson IJB. Physiological concentrations of genistein stimulate the proliferation and protect against free radical-induced oxidative damage of MC3T3-E1 osteoblast-like cells. Nutr Res. 2001; 21(9): 1287-1298.

37. Zheng WY, Nie SP, Li WJ, et al. Stimulatory effects of genistein and quercetin on the proliferation of MCF-7 cells. Food Biosci. 2013; 2: 15-23.